TRITON and beyond: new insights into the profile of prasugrel.

ABSTRACT: Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). This article reviews and discusses select components of a large literature of prasugrel data that has emerged since the TRITON-TIMI 38 (TRITON) study primary disclosure.

SUBMITTER: Jakubowski JA 

PROVIDER: S-EPMC3440581 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature